Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Stryker (SYK)

Stryker Q2 sales rise 9.4% to $6.6 billion; adjusted EPS up 17.9% to $3.69

Positive Impact 3 of 5 earnings Written later

Stryker reported second quarter 2026 net sales of $6.6 billion, up 9.4% from a year earlier, with reported diluted EPS of $3.30 and adjusted diluted EPS of $3.69. The company narrowed its full year 2026 guidance to organic net sales growth of 8.3% to 9.3% and adjusted diluted EPS of $14.95 to $15.10, and its CEO said the company is recovering from the cyber incident first reported on March 11, 2026.

Key points

  • Net sales $6.6 billion, up 9.4% (organic up 9.0%); MedSurg and Neurotechnology $3.6 billion, Orthopaedics $3.0 billion
  • Reported diluted EPS $3.30, up 44.1%; adjusted diluted EPS $3.69, up 17.9%
  • 2026 guidance narrowed: organic net sales growth 8.3% to 9.3%; adjusted diluted EPS $14.95 to $15.10

The filing

CompanyStryker (SYK)
Form8-K, current report
Filed with the SECJul 30, 2026, 4:09 PM ET
Accession number0000310764-26-000048

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.